1.40
전일 마감가:
$1.38
열려 있는:
$1.37
하루 거래량:
34,016
Relative Volume:
0.27
시가총액:
$42.14M
수익:
-
순이익/손실:
$-60.70M
주가수익비율:
-0.6863
EPS:
-2.04
순현금흐름:
$-61.05M
1주 성능:
-7.89%
1개월 성능:
+22.81%
6개월 성능:
+33.33%
1년 성능:
-58.82%
An 2 Therapeutics Inc Stock (ANTX) Company Profile
명칭
An 2 Therapeutics Inc
전화
(650) 331-9090
주소
1800 EL CAMINO REAL, SUITE D, MENLO PARK
ANTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ANTX
An 2 Therapeutics Inc
|
1.40 | 42.14M | 0 | -60.70M | -61.05M | -2.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
2024-08-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2024-07-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-04-02 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2024-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2024-02-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2024-02-12 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2024-02-12 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-01-04 | 개시 | JMP Securities | Mkt Outperform |
2022-07-18 | 재개 | Oppenheimer | Outperform |
모두보기
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - Quantisnow
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - Yahoo Finance
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Quantisnow
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - Yahoo Finance
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - The Manila Times
Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - Yahoo Finance
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - Yahoo Finance
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - Yahoo Finance
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire
Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - Yahoo Finance
Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics - Equitypandit
Latest News | Sun Pharma Shares Rise over 2 Pc as Company to Acquire Checkpoint Therapeutics - LatestLY
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - Yahoo Finance
Black Diamond Therapeutics Reports Fourth Quarter and Full - GlobeNewswire
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open - Yahoo Finance
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - BioSpace
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - Insider Monkey
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial resultsICYMI - Proactive Investors USA
Silver Bullet Therapeutics Announces Podcast Scheduled to Air on March 2, 2025 - Yahoo Finance
Cognition Therapeutics Successfully Passes Pre-defined - GlobeNewswire
Medicenna Therapeutics Corp. - Baystreet.ca
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients - Yahoo Finance
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
Cardiol Therapeutics Inc. - Baystreet.ca
2025-02-16 | APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit | NDAQ:APLT | Press Release - Stockhouse Publishing
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting - Yahoo Finance
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewswire
Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase II - Yahoo Finance
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025 - Yahoo Finance
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - Yahoo Finance
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD (NASDAQ:COYA) - Seeking Alpha
Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer - Yahoo Finance
Breakthrough Ovarian Cancer Drug Shows 14-Month Durability: Allarity Advances Clinical Trial - Stock Titan
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring - Seeking Alpha
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PR Newswire
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis - Yahoo Finance
Tectonic Therapeutic Announces Positive Interim Data from - GlobeNewswire
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of - GlobeNewswire
Major Setback: CARGO's Cancer Treatment Shows Alarming Safety Issues, Forces Company Restructure - StockTitan
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
APLT Lead Plaintiff Deadline ApproachingContact Robbins LLP for Information About the Pending Class Action Against Applied Therapeutics, Inc. - The Malaysian Reserve
An 2 Therapeutics Inc (ANTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):